Bryleos (fka BioNADrx), a Nashville, TN-based clinical stage therapeutics company, raised $5M in Seed funding.
The backers included early investor, television personality and former motorsport team owner Eddie Jordan.
The company intends to use the funds to develop its novel oral composition of NAD+, BNAD101.
Led by Wendy Komac, CEO and Founder, Bryleos is a clinical stage therapeutics company whose lead asset, BNAD101, is a patent-pending, novel oral composition of NAD+, clinically proven to significantly increase intracellular NAD levels in 5-days. In 2022, the company completed its Proof-of-Concept Study (“POC”) (n=60) with the Institute of Systems Biology. Overall, this POC generated a substantial set of novel findings that support its strategy and claims and provides further evidence for the critical role of NAD across several organ systems and biological pathways.
FinSMEs